{
  "title": "Vaccines Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)",
  "slug": "vaccines-market",
  "industry": "Pharmaceuticals & Therapeutics",
  "parent_industry": "Healthcare (Pharma, Medical Devices, Biotech)",
  "url": "https://www.mordorintelligence.com/industry-reports/vaccines-market",
  "scraped_at": "2026-09-17T17:43:20+07:00",
  "dataset_properties": [
    {
      "@type": "PropertyValue",
      "name": "Market Size (2026)",
      "value": 96.24,
      "unitText": "USD Billion"
    },
    {
      "@type": "PropertyValue",
      "name": "Market Size (2031)",
      "value": 134.85,
      "unitText": "USD Billion"
    },
    {
      "@type": "PropertyValue",
      "name": "Growth Rate (2026 - 2031)",
      "value": 6.98,
      "unitText": "PERCENT"
    },
    {
      "@type": "PropertyValue",
      "name": "Fastest Growing Market",
      "value": "Asia Pacific"
    },
    {
      "@type": "PropertyValue",
      "name": "Largest Market",
      "value": "North America"
    },
    {
      "@type": "PropertyValue",
      "name": "Market Concentration",
      "value": "Medium"
    }
  ],
  "faq": [
    {
      "@type": "Question",
      "name": "What is the current global value of the vaccines market?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The vaccines market size stands at USD 96.24 billion in 2026 and is projected to reach USD 134.85 billion by 2031."
      }
    },
    {
      "@type": "Question",
      "name": "Which segment is expanding fastest within vaccines?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Adult immunization is advancing at an 11.31% CAGR, driven by RSV, shingles, and pneumococcal boosters."
      }
    },
    {
      "@type": "Question",
      "name": "How are mRNA technologies reshaping vaccine economics?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Repurposed mRNA facilities now compress development timelines to under three years and support high-margin adult launches such as RSV boosters."
      }
    },
    {
      "@type": "Question",
      "name": "Why do multivalent vaccines dominate pediatric schedules?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "By combining up to six antigens per shot, multivalent formulations cut clinic visits, improve compliance, and currently account for two-thirds of pediatric doses."
      }
    },
    {
      "@type": "Question",
      "name": "Which regions show the highest growth potential?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Asia-Pacific leads with an 8.96% CAGR, propelled by large-scale manufacturing in India and China and expanding adult mandates in Japan, Australia, and South Korea."
      }
    }
  ],
  "images": [
    "images/vaccines-market-size.png",
    "images/vaccines-market-major-players.png",
    "images/vaccines-market-share-by-technology.png",
    "images/vaccines-market-share-by-disease-indication.png",
    "images/vaccines-market-share-by-end-user.png",
    "images/vaccines-market-growth-rate-by-region.png",
    "images/vaccines-market-competitive-landscape-market-concentration.png",
    "images/market-snapshot.png",
    "images/pdf3.png",
    "images/Esomar-25.png",
    "images/GPTW-25-3xl.png",
    "images/vaccines-market-size.png"
  ],
  "sections_count": 11
}